Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   12/03/2026
70,36 USD (-4,05%)
(-4,05%)   12/03/2026

12 maart 2026 · Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results · Persbericht

12 maart 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR · Persbericht

12 maart 2026 · NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

7 maart 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

27 februari 2026 · Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets · Persbericht

25 februari 2026 · Nektar Therapeutics to Participate in Two Investor Conferences in March · Persbericht

17 februari 2026 · Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis · Persbericht

13 februari 2026 · Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

12 februari 2026 · Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering · Persbericht

10 februari 2026 · Nektar Therapeutics Announces Proposed Public Offering · Persbericht

10 februari 2026 · New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing · Persbericht

9 februari 2026 · Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 · Persbericht

30 januari 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

16 december 2025 · REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata · Persbericht

16 december 2025 · Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 · Persbericht

6 december 2025 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 november 2025 · New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting · Persbericht

6 november 2025 · Nektar Therapeutics Reports Third Quarter 2025 Financial Results · Persbericht

30 oktober 2025 · Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London · Persbericht

28 oktober 2025 · Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets · Persbericht

Mijn selecties